Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 20/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 19/20 | 1.00 |
| ▸ | PIK3R2 | O00459 | 6/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.70 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628971 | 0.91 | PIK3CD (1.00) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16628977 | 0.89 | PIK3CD (1.00) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL19413078 | 0.87 | PIK3CD (0.80) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL17987922 | 0.85 | PIK3CG (0.81) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16630196 | 0.83 | PIK3CD (0.82) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16630042 | 0.83 | PIK3CD (0.82) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16630449 | 0.83 | PIK3CD (0.82) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16628965 | 0.83 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16664230 | 0.83 | PIK3CD (0.81) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB | |
| SCHEMBL16664171 | 0.83 | PIK3CD (0.81) | PIK3CGPIK3CDPIK3R2PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751888-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| WO-2015051241-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222016-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIK3CG 7/4885PIK3CD 2/4885PIK3R2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.